In this episode of the Xtalks Life Science Podcast, part of the Breakthrough with Dr. Corey Stanton series, host Dr. Corey Stanton sits down with Dr. Omar Wahab, Vice President of Bioprocessing at Lonza, to explore the increasingly strategic role of cell culture media in enabling scalable biologics manufacturing.
As biologics pipelines continue to expand across therapeutic areas such as oncology, immunology and advanced therapies, upstream development decisions are taking on new importance in determining manufacturing readiness, supply resilience and long-term commercial viability.
Drawing on more than two decades of experience spanning research, manufacturing, MSAT and commercial leadership, Dr. Wahab discusses how early formulation choices can shape downstream productivity, influence product quality attributes and ultimately impact cost of goods.
He underscores why media development should be viewed not as a routine procurement decision but as a core element of process design. This is particularly important as intensified production platforms and higher cell densities increase sensitivity to raw material variability and operational conditions.
The conversation examines the operational pressures facing today’s bioprocessing teams, including the need to advance clinical programs rapidly while maintaining confidence in scalability and regulatory expectations.
Dr. Wahab highlights how structured experimentation frameworks, such as Design of Experiments, are helping organizations generate more actionable data and move beyond traditional trial-and-error approaches.
He also points to the importance of aligning upstream innovation with real-world manufacturing considerations, from large-scale process feasibility to globally sustainable material sourcing strategies.
Listeners will also gain insight into how non-GMP and GMP manufacturing stages function as critical transition points between early development insights and regulated commercial production. When formulation strategies are developed with downstream execution in mind, companies can reduce late-stage comparability challenges and strengthen supply continuity across global manufacturing networks.
Dr. Wahab further discusses the growing role of digital tools and structured data environments in improving process visibility and enabling more coordinated decision-making across development and production teams.
Looking ahead, Dr. Wahab shares his perspective on the trends set to define the next phase of upstream bioprocessing, including tighter integration between development and manufacturing functions and the rising strategic significance of regional biologics hubs such as Singapore.
He notes that future success in biologics manufacturing will depend not only on scientific excellence but also on cross-functional alignment and a systems-level understanding of how early upstream decisions influence performance at commercial scale.
Tune in to learn how structured media development strategies help life sciences organizations accelerate timelines, reduce technical risk and strengthen confidence as programs move toward commercial biologics production.
The weekly podcast is available for streaming every Wednesday on Spotify, Apple Music and wherever you stream your podcasts.
Subscribe to the Xtalks Life Science Podcast to never miss a new episode.
Join or login to leave a comment
JOIN LOGIN